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Genes Associated with Recurrence of Hepatocellular Carcinoma: 
Integrated Analysis by Gene Expression and Methylation Profiling
Gene expression is suppressed by DNA methylation. The goal of this study was to identify 
genes whose CpG site methylation and mRNA expression are associated with recurrence 
after surgical resection for hepatocellular carcinoma (HCC). Sixty-two HCCs were examined 
by both whole genome DNA methylation and transcriptome analysis. The Cox model was 
used to select genes associated with recurrence. A validation was performed in an 
independent cohort of 66 HCC patients. Among fifty-nine common genes, increased CpG 
site methylation and decreased mRNA expression were associated with recurrence for 12 
genes (Group A), whereas decreased CpG site methylation and increased mRNA expression 
were associated with recurrence for 25 genes (Group B). The remaining 22 genes were 
defined as Group C. Complement factor H (CFH) and myosin VIIA and Rab interacting 
protein (MYRIP) in Group A; proline/serine-rich coiled-coil 1 (PSRC1), meiotic 
recombination 11 homolog A (MRE11A), and myosin IE (MYO1E) in Group B; and 
autophagy-related protein LC3 A (MAP1LC3A), and NADH dehydrogenase 1 alpha 
subcomplex assembly factor 1 (NDUFAF1) in Group C were validated. In conclusion, 
potential tumor suppressor (CFH, MYRIP) and oncogenes (PSRC1, MRE11A, MYO1E) in 
HCC are reported. The regulation of individual genes by methylation in 
hepatocarcinogenesis needs to be validated.
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Hepatocellular carcinoma (HCC) is the seventh most common 
cancer and the third leading cause of cancer related mortality 
in the world (1). However, the mechanisms of liver cancer initi-
ation and progression are incompletely elucidated. DNA meth-
ylation is one of the major mechanisms for the epigenetic sup-
pression of gene activity during carcinogenesis. Methylation of 
tumor suppressor genes has the potential to be used as a bio-
marker for cancer detection as well as a prognostic marker in 
cancer (2). An increasing number of putative tumor suppressor 
genes have been reported to be down regulated by promoter 
CpG island methylation in HCC. Hypomethylation can also be 
implicated in tumorigenesis through the activation of oncogenes 
and local increases in chromosomal instability. 
  Comparative and integrative functional genomics using ge-
nome wide microarray analysis methods have improved the 
molecular classification and prognostic prediction of HCC (3, 4). 
Recently, array based technology assessing genome-wide DNA 
methylation has been used to identify genes that are silenced 
by methylation in HCC (5, 6). Recent studies have also shown 
that particular methylation patterns revealed through genome 
wide DNA methylation array analysis are associated with can-
cer risk and poor prognosis in HCC (5).  
  In this study, we hypothesized that epigenetic changes in in-
dividual genes, (CpG site hypermethylation of tumor suppres-
sor genes and hypomethylation of oncogenes), are associated 
with HCC recurrence after surgical resection with curative in-Yang JD, et al.  •  Genes Associated with Recurrence of HCC
http://jkms.org   1429 http://dx.doi.org/10.3346/jkms.2011.26.11.1428
tent. To test our hypothesis, we obtained gene expression and 
methylation profiling data using surgically-resected HCC tis-
sues. Genes whose methylation and expression are associated 
with recurrence were identified in the training data set and vali-
dated in an independent data set. In addition, we aimed to iden-
tify pathways enriched by recurrence predicting genes using 
mRNA expression and CpG site methylation. 
 
MATERIALS AND METHODS
Patients 
Patients included in this study were treated with surgical resec-
tion for HCC between December, 2001 and December 2007 at a 
single institution, Keimyung University Dong-San Medical Cen-
ter, Daegu, Korea. A total of 169 patients had resection with cu-
rative intent during the period and gene expression and meth-
ylation profiling were available from 62 HCC tissues for the anal-
yses.  
  Clinical and laboratory data including histopathology at HCC 
diagnosis and information on recurrence and survival after re-
section were collected. After surgery, the patients were seen ev-
ery three to six months for assessment of tumor recurrence us-
ing serum alpha-fetoprotein, PIVKA-II, and high-resolution 
multi-detector CT. Validation of recurrence predicting genes 
was performed using data previously published by Lee et al. (4) 
which includes gene expression profiles of 139 HCCs. Data on 
tumor recurrence was available for 66 of the 139 patients and 
was used for the validation. As methylation profiling data was 
not available in the validation data set, only the association be-
tween mRNA expression and recurrence could be validated. 
Transcriptome profiling 
The process of transcriptome profiling was described in our pre-
vious study (7). Briefly, total RNA from liver cancer samples was 
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). 
Labeled, amplified material (1,500 ng per array) was hybridized 
to Version 3 of the Illumina Human-6 BeadChip (48 K) (Illumi-
na Inc., San Diego, CA, USA). Array signals were developed us-
ing Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-
Sciences, Little Chalfont, UK). Arrays were scanned with an Illu-
mina BeadArray Reader confocal scanner (BeadStation 500-
GXDW; Illumina, Inc.). Gene expression profiles of 48,803 probes 
from 62 individual HCC tissue samples were obtained. Transcrip-
tome profiling for the validation set has also been previously re-
ported (4). RNA from HCC and adjacent benign tissue from the 
139 HCCs was analyzed at the US National Cancer Institute us-
ing the Qiagen Human Array-Ready Oligo Set (version 2.0), which 
contains 70-mer probes for 21,329 genes. CsCl density-gradient 
centrifugation was used to isolate total RNAs from frozen liver 
tissue. Total RNA from 19 normal livers was used as the refer-
ence for all microarray experiments. 
DNA samples for whole genome methylation analysis 
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, 
Valencia, CA, USA). The quality of genomic DNA was checked 
by gel electrophoresis and DNA concentrations were determined 
using the Ultrospec 3100 pro spectrophotometer (Amersham 
Bioscience, Buckinghamshire, UK).
Bisulfite conversion of DNA and BeadArray technology 
The EZ DNA methylation kit (Zymo Research, Orange, CA, USA) 
was used for bisulfite conversion of 2 µg of genomic DNA. After 
bisulfite treatment, the remaining assay steps were identical to 
the GoldenGate genotyping assay using Illumina-supplied re-
agents and conditions (8). 5 µL of the converted DNA was used 
with the Infinium HumanMethylation27 v1.0 BeadChip array 
from Illumina to genotype bisulfite-converted and unconverted 
CpGs. 
  The DNA was biotinylated and purified from excess biotin. 
Assay oligonucleotides were added and hybridized to resus-
pended DNA. Allele-specific extension and ligation of the hy-
bridized oligos was performed; fluor-labeled strands were then 
hybridized to the Illumina HumanMethylation27 BeadChip. 
Arrays were scanned with an Illumina BeadArray Reader con-
focal scanner. The chip interrogates 27,578 CpG sites of over 
14,000 genes. 
Statististics for survival
Gene expression microarray data pre-processing was performed 
using Illumina BeadStudio software version 3. The un-normal-
ized and non-background subtracted data was then normalized 
using the quantile normalization method in the Linear Models 
for Microarray Data (LIMMA) package in the R language environ-
ment. The Cox proportional hazards model was used to select 
genes that were significantly associated with recurrence. Patients 
without an event at the time of last follow-up were treated as 
censored. The hazard ratio and nominal P value were obtained 
for each gene. As the gene expression data was in log2 scale, the 
hazard ratio (HR) represented an increased or decreased risk as 
gene expression value doubled. 
  As methylation status per tested locus was reported as a ratio 
from 0 to 1, it was transformed into a 1 to 10 scale so that every 
one unit of increase or decrease represented a 10% methylation 
difference for the estimated hazard ratio from the Cox propor-
tional hazards model. Fig. 1 schematically illustrates the experi-
mental design and analytical steps. Individual genes for which 
the expression or methylation status in the training set was asso-
ciated with significant differences in recurrence-free survival 
were identified. The independent data set was used to validate 
the association of mRNA expression of the individual genes se-
lected in the training set with recurrence. All analyses were con-
ducted using the R statistical package (http://www.r-project.org/) 
or Partek
® genomic software suite.Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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Statistics for pathway analysis
MetaCore software (http://www.genego.com/metacore.php) 
was used to investigate the pathways associated with recurrence 
predicting gene sets by mRNA expression and CpG site methyl-
ation using the default Metacore reference database. Pathways 
with which the recurrence predicting genes were associated 
more highly than would be expected by chance were identified. 
The significance of the association with pathway was estimated 
by hypergeometric test P value. 
Ethics statement 
The study protocol was approved by the institutional review board 
for the use of human subjects at the Keimyung University School 
of Medicine (IRB No: 08-122). 
  All participants provided written informed consent. 
RESULTS
Clinical characteristics of the patients
Table 1 summarizes the clinical characteristics of the patients in 
this study. The median age was 56 yr and there was a strong male 
Step 1. Training phase
Cox-propotional hazard model
Training set (n = 62)
   1. 48,803 gene expression and 27,578 methylation profiles were obtained from 62HCCs.
   2. Individual genes affecting recurrence by expression or methylation were selected using  
          Partek software.
Validation set (n = 62)
   1. 20,808 gene expression (tumor/benign) ratio were obtained from 66 HCCs and adhacent 
          benign tissues
   2. Genes selected from the training phase were validated in the independent data set
Group A
Gene associated with recurrence by under 
expression and hypermethylation
Group B
Gene associated with recurrence by over 
expression and hypomethylation
Group C
Gene associated with recurrence either over 
expression hypemethylation for under 
expression and hypomethylation
Step 2. Testing phase
Fig. 1. Flow chart of the experimental protocol.
Table 1. Demographic and clinicopathologic characteristics of the 62 HCC training set patients 
Characteristics Data
Age (yr) 56.0 ± 10.2 (31-77)
Sex
   Male
   Female
 
   46 (74.2%)
   16 (25.8%)
Causes of underlying liver disease 
   HBV
   HCV
   HBV/HCV combined
   Alcohol
   Unknown
 
47 (75%)
   3 (4.8%)
   1 (1.6%)
   3 (4.8%)
     8 (12.9%)
AFP (ng/mL)
    < 10  
   10 >=,  < 400
    >= 400
    3756 ± 13226
   17 (27.4%)
   28 (45.2%)
   17 (27.4%)
AST (IU/mL)
ALT (IU/mL)
ICG R15(%)
    < 10
    => 10
  52.1 ± 39.4
  42.2 ± 22.5
11.3 ± 6.1
   27 (43.5%)
   35 (56.5%)
Cirrhosis 
   Yes
   No
 
   40 (64.5%)
   22 (35.4%)
Data shown as mean ± standard deviation (range) or median [inter quartile range] for continuous variable and proportion (%) for categorical variables *Median [interquartile range]. 
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase; ICG, indocyanine green test.
Characteristics Data
Size of tumor (cm)   5.9 ± 4.0
Number of tumor
   1
   2
   3
   4
   5
 
   53 (85.5%)
   5 (8.1%)
   2 (3.2%)
   1 (1.6%)
   1 (1.6%)
Edmonson-Steiner Grade
   1
   2
   3
   4
 
   2 (3.4%)
   36 (61.0%)
   19 (33.9%)
   2 (3.4%)
Stage (TNM)
   1
   2
   3
 
   35 (56.5%)
   19 (30.6%)
     8 (12.8%)
Recurrence
   Yes
   No
 
   37 (59.7%)
   25 (40.5%)
Recurrence free survival (months)     23.5 [7.0-74.1]* 
Overall survival (months) 66.2 [22.7- ]*Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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preponderance. All patients were Asian and HBV was the most 
common etiology of HCC. More than 85% of the patients had a 
single lesion and stage 1 or stage 2 HCC. Recurrence developed 
in 60% of patients with a median follow up of 20.2 months. The 
median overall survival was 66.2 months and the median recur-
rence-free survival was 23.5 months. Clinical characteristics of 
the patients in the validation data set were reported in the pre-
vious study (4). Briefly, the median age was 57 yr and 73% were 
male. HBV (56%) was the most common etiology. In contrast to 
the training cohort, only 44% were Asian. Recurrence developed 
in 65% of patients with a median follow up of 24.6 months. 
Genes whose mRNA expression and CpG site methylation 
associated with recurrence and pathway enriched by 
recurrence predicting genes
At a P value < 0.05, 3,876 genes were associated with recurrence 
by mRNA expression. These genes were enriched in cytoskele-
ton remodeling processes through TGF, Wnt, and cytoskeletal 
remodeling; immune response through classic, alternative, and 
lecitin induced complement pathways; the cell cycle through 
metaphase check point, and spindle assembly and chromosome 
separation; and blood coagulation, VEGF, and androgen recep-
tor nuclear signaling pathways.
  Similarly, genes that were significantly associated with recur-
rence by methylation were selected. At a P value < 0.05, 541 CpG 
sites were included in this category. Pathways enriched in genes 
regulated by the 541 recurrence predicting CpG sites were de-
velopment through IGF-1R, FGFR, PIP3, and Wnt; signal trans-
duction through AKT and PTEN; cytoskeleton remodeling pro-
cess through TGF, Wnt, and cytoskletal remodeling; immune 
response through PIP3 signaling in B cells; proteolysis through 
ubiquitin; and transcription through CREB Pathways. Of note, 
the cytoskeleton remodeling_TGF, Wnt, and cytoskeletal remod-
eling pathway was enriched in both recurrence predicting gene 
sets (Table 2). 
Common genes for which both methylation and mRNA 
expression were associated with recurrence 
Fifty-nine genes were associated with recurrence by both CpG 
site methylation and mRNA expression (Fig. 2). These common 
genes were classified into three groups. Group A includes 12 genes 
for which both increased CpG site methylation and decreased 
mRNA expression were associated with recurrence (Table 3). 
Group B includes 25 genes for which both decreased gene meth-
Table 2. Top ten signaling pathways enriched by recurrence predicting gene by mRNA expression or CpG site methylation
Recurrence predicting gene by mRNA expression Recurrence predicting gene by CpG site Methylation
Pathways P value Pathways P value
Cytoskeleton remodeling: TGF, WNT, and cytoskeletal remodeling 3.2E-07 Development: IGF1 receptor signaling 2.8E-05
Immune response: alternative complement pathways 3.9E-07 Development: FGFR signaling pathways 3.7E-05
Immune response: lectin induced complement pathways 1.2E-06 Signal transduction: AKT signaling  1.0E-04
Immune response: classical complement pathways 2.6E-06 Cytoskeleton remodeling: TGF,WNT, and cytoskeletal remodeling 1.5E-04
Blood coagulation:  Blood coagulation 1.9E-05 Development: PIP3 signaling in cardiac myocyte 1.7E-04
Cell cycle: metaphase check point 5.3E-05 Development: WNT  signaling pathways 3.7E-04
Cytoskeleton remodeling: cytoskeleton remodeling 6.0E-05 Proteolysis: Putative ubiquitin pathways 6.5E-04
Cell cycle: spindle assembly and chromosome separation  1.5E-04 Immune response: PIP3 signaling in B lymphocytes 8.2E-04
Development: VEGF-family signaling 1.8E-04 Transcription: CREB pathways  1.0E-03
Transcription: androgen receptor nuclear signaling 4.0E-04 Signal transduction: PTEN pathways 1.3E-03
Table 3. Twelve genes (Group A) for which both increased CpG site methylation and decreased mRNA expression were associated with recurrence of HCC
Gene symbol                           Annotation
 Training set Testing set
 Methylation Expression Expression
HR P value HR P value HR P value
MYRIP Myosin VIIA and Rab interacting protein 1.84 0.01 0.15 0.02 0.65 < 0.01
CFH Complement factor H isoform a precursor 1.44 0.01 0.65 0.001 0.64 < 0.01
MRPL4 Mitochondrial ribosomal protein L4 isoform a 39.9 0.04 0.3 0.01 None
THBS1 Thrombospondin 1 precursor 11.7 0.02 0.76 0.04 1.83 0.09
GPSN2 Glycoprotein; synaptic 2 5.05 0.01 0.47 0.03 None
CHKA Choline kinase alpha isoform a 3.09 0.02 0.09 0.03 0.82 0.4
TIMP3 Tissue inhibitor of metalloproteinase 3 precursor 2.33 0.04 0.62 < 0.01 1.4 0.2
PCDHB11 Protocadherin beta 11 precursor 2.25 < 0.01 0.16 0.01 None
HSD17B6 3-hydroxysteroid epimerase 1.39 0.04 0.84 0.02 None
KLK10 Kallikrein 10 precursor 1.28 0.04 0.1 0.04 0.96 0.93
CYGB Cytoglobin 1.24 0.03 0.6 0.03 None
FXYD1 Phospholemman precursor 1.19 0.02 0.69 0.04 0.92 0.62
HR, hazard ratio.Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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ylation and increased mRNA expression were associated with 
recurrence (Table 4). We also defined Group C genes for which 
both decreased CpG site methylation and mRNA expression or 
both increased CpG site methylation and mRNA expression were 
Validation
Common genes (n = 59)
Genes associated with recurrence by 
both gene expression and methlation
Group A (n = 12)
Genes associated with recurrence by 
under expression and hypermethylation
MYRIP, CFH
Genes associated with recurrence by 
under expression in the validation data set
Group B (n = 22)
Genes associated with recurrence by 
over expression and hypermethylation or under 
expression and hypermethylation
MAPLC3A, NDUFAF1
Genes associated with recurrence by 
under or over expression in the validation data set
Group B (n = 59)
Genes associated with recurrence by 
over expression and hypomethylation
PSRC1, MRE11A, MYO1E
Genes associated with recurrence by 
over expression in the validation data set
Fig. 2. Selection of recurrence associated genes in the training and validation data set. MYRIP, Myosin VIIA and Rab interacting protein; CFH, Complement factor H; PSRC1, 
Proline/serine-rich coiled-coil 1; MRE11A, Meiotic recombination 11 homolog A; MYO1E, Myosin IE; MAP1LC3A, autophagy-related protein LC3 A; NDUFAF1, NADH dehydro-
genase 1 alpha subcomplex assembly factor 1.
Table 4. Twenty-five genes (Group B) for which both decreased CpG site methylation and increased mRNA expression were associated with recurrence of HCC 
Gene symbol                           Annotation
Training Set Testing Set
Methylation Expression Expression
HR P value HR P value HR P value
PSRC1 p53-regulated DDA3 isoform a 4.19E-07 0.04 4.59 0.01 3.16 0.03
MRE11A Meiotic recombination 11 homolog A isoform 1 6.61E-04 0.03 4.59 0.01 2.10 0.02
MYO1E Myosin IE  0.01 0.02 11.4 0.01 2.49 < 0.01
NR2C1 Nuclear receptor subfamily 2; group C; 
   member 1 isoform a
1.61E-10 0.01 2.82 0.04 2.25 0.09
NSUN4 NOL1/NOP2/Sun domain family 4 protein 1.13E-07 0.01 2.01 0.03 1.92 0.17
C6orf192 Hypothetical protein LOC116843 2.30E-06 0.02 1.84 0.01 0.92 0.90
C1orf156 Hypothetical protein MGC9084 6.03E-05 0.01 5.23 0.02 0.89 0.85
NUP43 Nucleoporin 43 kDa 7.11E-05 0.02 2.68 0.01 1.43 0.35
RDH14 Retinol dehydrogenase 14 (all-trans and 9-cis) 1.38E-04 < 0.01 0.006 < 0.01 0.46 0.19
COPS8 COP9 signalosome subunit 8 isoform 1 2.99E-04 0.01 10.7 0.02 0.67 0.03
METTL2B Methyltransferase like 2 3.27E-04 0.02 14.6 < 0.01 0.92 0.89
MED18 Mediator of RNA polymerase II transcription; 
   subunit 18 homolog
4.86E-04 0.03 3.65 0.03 1.00 0.99
CBX8 Chromobox homolog 8 4.90E-04 0.02 2.26 0.01 0.51 0.18
EIF2B5 Eukaryotic translation initiation factor 2B; 
   subunit 5 epsilon; 82 kDa
5.17E-04 0.01 2.74 0.01 0.81 0.72
EYA3 Eyes absent 3 6.94E-04 0.04 6.43 < 0.01 3.21 0.07
CHD6 Chromodomain helicase DNA binding protein 6   0.001 0.04 2.48 0.02 1.38 0.50
QARS Glutaminyl-tRNA synthetase   0.001 0.04 2.01 0.04 0.72 0.31
AMPD2 Adenosine monophosphate deaminase 2 
   (isoform L) isoform 3
0.01 0.03 15.3 < 0.01 1.34 0.33
LRIG2 Leucine-rich repeats and immunoglobulin-like 
   domains 2
0.02 0.02 6.65 < 0.01 1.36 0.17
SERAC1 Serine active site containing 1 0.41 0.02 9.01 0.01 1.65 0.34
SLC45A2 Membrane-associated transporter protein 
   isoform a
0.61 0.03 2.07 0.01 0.94 0.9
DNMT3B DNA cytosine-5 methyltransferase 3 beta 
   isoform 1
0.74 0.01 2.41 0.04 2.21 0.17
NMB Neuromedin B isoform 1 0.80 0.03 1.83 0.01 None
FANCG Fanconi anemia; complementation group G 0.83 0.02 2.40 0.01 2.59 0.05
SMAD2 Sma- and Mad-related protein 2 0.87 0.03 5.65 0.04 0.54 0.11
HR, hazard ratio.Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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associated with recurrence (Table 5).
  Kaplan-Meier curves were generated using the training data 
set and recurrence-free survival was compared between groups 
classified above or below the median (the 31 patients with above 
median mRNA expression vs the other 31 patients with below 
median gene expression; and the 31 patients with above medi-
an CpG site methylation vs the other 31 patients with below me-
dian CpG site methylation) using the log rank test (Fig. 3). Some 
of the genes show significant differences in recurrence free sur-
vival (MRE11A & CFH) when expression/methylation patterns 
were dichotomized.
Validation 
The validation data set were used to examine whether the mRNA 
expression of the 59 common genes were associated with recur-
rence of HCC in an independent data set. Down-regulation of 
myosin VIIA and Rab interacting protein (MYRIP) and comple-
ment factor H (CFH) in Group A; up-regulation of proline/ser-
ine-rich coiled-coil 1 (PSRC1), meiotic recombination 11 homo-
log A (MRE11A), and myosin IE (MYO1E) in Group B; and down 
regulation of autophagy-related protein LC3 A (MAP1LC3A), 
and NADH dehydrogenase 1 alpha subcomplex assembly fac-
tor 1 (NDUFAF1) in Group C were associated with recurrence 
in the validation data set. Mitochondrial ribosomal protein L4 
(MRPL4), protocadherin beta 11 (PCDHB11), synaptic glyco-
protein SC2 (GPSN2), cytoglobin (CYGB), hydroxysteroid 17-
beta dehydrogenase 6 (HSD17B6) in Group A and neuromedin 
B (NMB) in Group B, morf4 family associated protein 1-like 1 
(MRFAP1L1), cancer/testis antigen 45-2 (CT45-2), CD20 anti-
gen-like protein (MS4A3), and neurotrimin (HNT) in Group C 
could not be validated due to the absence of a corresponding 
oligonucleotide in the validation data set. 
DISCUSSION
In this study, we have first identified two sets of recurrence pre-
dicting genes by 1) mRNA expression, and 2) promoter CpG site 
methylation. We identified pathways enriched in the two sets of 
recurrence predicting genes and also identified genes common 
to both the mRNA and CpG methylation analyses. Among 59 
common genes, Genes in Group A were considered to be poten-
tial tumor suppressors since both CpG hypermethylation and 
down regulation of mRNA expression were associated with re-
currence. In contrast, genes in Group B were considered to be 
potential oncogenes because CpG hypomethylation and in-
creased mRNA expression were associated with recurrence. We 
will first discuss the relevant pathways enriched by recurrence 
Table 5. Twenty-two genes (Group C) for which both decreased CpG site methylation and decreased mRNA expression or both increased CpG site methylation and increased 
mRNA expression were associated with recurrence of HCC 
Gene symbol                          Annotation
Training Set Testing Set
Methylation Expression Expression
HR P value HR P value HR P value
MAP1LC3A Autophagy-related protein LC3 A 0.78 0.04 0.06 0.01 0.63 0.04
NDUFAF1 NADH dehydrogenase 1 alpha subcomplex, 
   assembly factor 1
0.83 0.03 0.50 0.03 0.27 < 0.01
BMF Bcl2 modifying factor 4.77E-05 0.05 0.13 0.04 1.14 0.52
MRFAP1L1 Morf4 family associated protein 1-like 1 3.01E-04 0.02 0.27 0.02 None
CLPP Endopeptidase Clp 3.02E-03 0.05 0.44 0.03 0.81 0.72
PECI Dodecenoyl-CoA isomerase 0.20 0.03 0.72 0.02 1.99 0.24
CT45-2 Cancer/testis antigen 45-2 0.61 0.02 0.05 < 0.01 None
MS4A3 CD20 antigen-like protein 0.63 0.02 0.10 0.03 None
PAPSS2 PAPS synthase 2 0.66 0.04 0.66 0.03 0.90 0.52
MAPKAP1 Mitogen-activated protein kinase associated 
   protein 1
0.68 0.04 0.45 0.04 0.84 0.66
MAGEA11 Melanoma antigen family A, 11 0.75 0.03 0.05 0.04 1.64 0.18
LCT Lactase-glycosylceramidase 0.76 0.02 0.06 0.02 0.94 0.87
THSD4 Thrombospondin, type I, domain containing 4 0.78 0.03 0.27 0.03 2.58 0.07
CLEC4A C-type lectin domain family 4, member A 0.80 0.03 0.15 0.01 2.69 0.03
SEMA3B Semaphorin-3B 1.15 0.04 2.56 0.01 0.77 0.54
HNT Neurotrimin 1.16 0.02 2.27 0.03 None
NEUROD2 Neurogenic differentiation 2 1.19 0.04 6.84 0.05 1.50 0.43
PCDHB14 Protocadherin beta 14 1.19 0.05 12.85 0.02 1.22 0.78
BDNF Brain-derived neurotrophic factor 1.20 < 0.01 9.29 0.03 1.31 0.75
TSSC1 Tumor suppressing subtransferable candidate 1 1.80 0.04 3.05 0.01 0.98 0.96
ZNF267 Zinc finger protein 267 1.81 0.05 9.40 0.04 1.46 0.26
STARD3NL STARD3 N-terminal-like protein 2.35 < 0.01 2.24 0.03 0.64 0.30
HR, hazard ratio.Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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predicting genes. Specific genes that have been reported to func-
tion as tumor suppressors or oncogenes in the scientific litera-
ture will be discussed next, followed by discussion of genes with-
out existing proof of tumor suppressor or oncogenic function.  
  Pathways enriched in recurrence predicting genes by mRNA 
expression include pathways critical in tumorigenesis and can-
cer progression such as the cytoskeleton remodeling, immune 
response, cell cycle, VEGF and androgen receptor signaling path-
ways (9). Some pathways enriched by recurrence predicting genes 
by CpG site methylation are major signaling pathways in HCC 
development, progression, and metastasis. These include IGF-
1R, FGFR, PIP3, Wnt, signal transduction through AKT and PTEN, 
cytoskeleton remodeling process through TGF, Wnt, and cyto-
skeletal remodeling pathways (9). Interestingly, the cytoskele-
ton remodeling TGF, Wnt, and cytoskeletal remodeling pathway 
was commonly enriched in both recurrence predicting gene sets. 
The Wnt and TGFβ pathways are major signaling pathways in 
HCC (3, 9). It is currently unknown whether CpG site methyla-
tion of genes involved in these pathways regulates the activity 
of these signaling pathways. This should be further investigated 
in future studies.  
  Proline/serine-rich coiled-coil 1 (PSRC1) is a micro-tubule-
associated oncoprotein that is transcriptionally down regulated 
by p53. Its promoter contains a putative p53 binding motif that 
is responsible for the p53 mediated repression of the gene (10). 
PSRC1 protein promotes cell growth by several different mech-
anisms. It enhances β-catenin dependent transactivation and 
cyclin D1 production by binding to adenomatous polyposis coli 
2 (APC2), a homolog of adenomatous polyposis coli (APC), which 
is a component of the β-catenin destruction complex (11). It also 
inhibits p53-binding protein 2 (ASPP2) induced apoptotic sig-
naling of p53 (12). Over expression of PSRC1 was observed in 
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Fig. 3. Effect of individual gene expression and methylation on recurrence free survival. Patients were divided into two groups based on their gene expression and methylation 
status (over expression vs under expression; hypermethylation vs hypomethylation). Recurrence-free survival was compared between two groups in the training data set. Group 
A and B genes associated with recurrence both in the training and validation data sets were included in the figure. (A) 31-patients with PSRC1 mRNA expression level above 
median is more likely develop recurrence than the other 31 patients with PSRC1 mRNA expression level below median (P = 0.05). On the other hand 31 patients with PSRC1 
CpG site methylation level above median is less likely to develop recurrence than the other 31 patients with PSRC1 CpG site methylation level below median (P = 0.06). (B) 
31-patients with MRE11A mRNA expression level above median is more likely develop recurrence than the other 31 patients with MRE11A mRNA expression level below medi-
an (P = 0.05). On the other hand 31 patients with MRE11A CpG site methylation level above median is less likely to develop recurrence than the other 31 patients with MRE11A 
CpG site methylation level below median (P = 0.05). (C) MYO1E mRNA expression level was not associated with recurrence when patients were dichotomized (P = 0.67). On the 
other hand 31 patients with MYO1E CpG site methylation level above median is less likely to develop recurrence than the other 31 patients with MYO1E CpG site methylation 
level below median (P = 0.06). (D) MYRIP mRNA expression level (P = 0.32) and CpG site methylation level (P = 0.79) were not associated with recurrence when patients were 
dichotomized. (E) 31-patients with CFH mRNA expression level above median is less likely develop recurrence than the other 31 patients with CFH mRNA expression level be-
low median (P = 0.02). On the other hand 31 patients with CFH CpG site methylation level above median is more likely to develop recurrence than the other 31 patients with 
PSRC1 CpG site methylation level below median (P = 0.02).Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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hepatoma tissues compared to the adjacent benign tissue (10). 
The mechanism of PSRC1 over-expression in HCC tissues is yet 
to be understood. Mutation of p53 may partly explain the up-reg-
ulation of PSRC1 in hepatoma tissues. Our study has shown that 
hypomethylation of the PSRC1 gene is associated with an in-
creased risk for recurrence. Furthermore, high expression of the 
PSRC1 gene was associated with shorter recurrence-free surviv-
al. This is the first report that increased expression of the PSRC1 
gene is associated with recurrence free survival in patients who 
underwent curative resection for HCC. The result also indirectly 
supports the concept that hypomethylation of PSRC1 may con-
tribute to the over-expression of PSRC1 and tumor progression 
in HCC.
  DNA methyltransferase 3β (DNMT3B) is a de novo methyl-
transferase that catalyzes the methylation of the CpG islands of 
genes. DNMT3B is highly expressed in HCC, but rarely expressed 
in normal liver and increased expression of DNMT3B is associat-
ed with poorer overall survival in HCC patients (13). Hypometh-
ylation of DNMT3B was associated with recurrence of HCC in 
our study. Our result also confirmed that increased expression 
of DNMT3B is associated with poor prognosis in HCC patients, 
although the validation analysis showed a similar trend with- 
  out statistical significance (P = 0.17). The mechanistic role of 
DNMT3B promoter hypomethylation and increased expression 
of DNMT3B in liver carcinogenesis remains to be determined.
  Tissue inhibitor of metalloproteinase 3 (TIMP3) is a well-known 
tumor suppressor gene in HCC. Tumor growth, invasion and 
metastatic tendency are restrained by the metalloproteinase in-
hibitory effect of TIMP3 and aberrant methylation of TIMP3 is 
observed in 25% of HCCs (14). In the training data set, hyper-
methylation and downregulation of TIMP3 were associated with 
recurrence, but the association of gene expression with recur-
rence was not validated in the independent data set. 
  Cytoglobin (CYGB) is a recently discovered globin protein and 
its function is not yet completely established. Shivapurkar et al. 
(15) have shown that CpG site methylation of the CYGB promot-
er region is associated with down regulation of gene expression 
and methylation of the gene had an excellent ability to differen-
tiate cancers of the breast, lung, bladder, and leukemia cells from 
benign tissues. Knockdown of the CYGB gene in a lung cancer 
cell line increased colony formation and transfection of CYGB 
led to decreased colony formation, suggesting a tumor suppres-
sor role of CYGB (15). In the liver, CYGB is highly expressed in 
hepatic stellate cells and its expression is associated with hepat-
ic fibrosis (16). CYGB appears to act as a scavenger of reactive 
oxygen species, preventing liver injury and resultant liver fibro-
sis by inhibiting free radical-induced hepatic stellate cell activa-
tion. Over expression of CYGB inhibits the differentiation of rat 
hepatic stellate cells into the myofibroblast-like phenotype, and 
protects against progressive liver damage and fibrosis (17). There 
has been no report of a role for CYGB in HCC pathogenesis as 
yet. It is plausible that down regulation of CYGB enhances liver 
fibrosis and cirrhosis in patients with chronic hepatitis and al-
lows the action of genotoxic reactive oxygen species, eventually 
contributing to the development of HCC. Although suppression 
of CYGB expression in HCC could not be validated due to the 
lack of a gene probe in the validation data set, this is the first study 
that suggests that CpG site methylation of CYGB and down reg-
ulation of CYGB are associated with the risk of recurrence after 
surgical resection for HCC.  
  Kallikrein-related peptidase 10 (KLK10) is a member of the 
human tissue kallikrein family of secreted serine proteases. 
KLK10 is known to function as a tumor suppressor and loss of 
KLK10 gene expression by CpG island methylation has been 
reported in breast, ovarian, and prostate cancer (18). KLK10 
methylation is an independent predictor of disease-free surviv-
al and overall survival in early-stage breast cancer patients (19). 
Lu et al. (20) recently reported that KLK10 is frequently down-
regulated by methylation in HCC. In their experiments, 20 to 
40% of CpG sites in the KLK10 gene were methylated in HCC 
cell lines compared to 2.1% of CpG sites in normal liver DNA. 
Hypermethylation of KLK10 was observed in 55% of 49 HCC 
samples and there was an inverse correlation between KLK10 
mRNA level and methylation (r = -0.435, P < 0.05). Interesting-
ly, transfection of the J7 cell line with KLK10 decreased anchor-
age-independent growth, and transfection of Huh7 cells with 
KLK10 increased the sensitivity of Huh7 cells to cytotoxic agents, 
suggesting a tumor suppressor effect of KLK10 in HCC tissues. 
In our analysis, hypermethylation and down regulation of KLK10 
was associated with HCC recurrence in the training data set. How-
ever, expression of KLK10 was not associated with recurrence 
in the validation data set. Determination of the true prognostic 
value of KLK10 methylation in HCCs requires further validation.  
  Complement factor H (CFH) regulates alternate pathways of 
complement activation. A CFH polymorphism has a strong as-
sociation with age-related macular degeneration. Mutation of 
CFH and resultant dysregulation of the complement system is 
also linked to atypical hemolytic uremic syndrome (21). The ex-
pression of CFH in adipose tissue correlates with insulin resis-
tance (21). Although the role of CFH in cancer is not well under-
stood, over-expression of CFH was associated with reduction of 
the metastatic and/or mortality risk (P = 0.036, HR 0.44) in soft 
tissue sarcomas (22). Our results suggest that CFH acts as a tumor 
suppressor and its expression may be down regulated by pro-
moter methylation. The mechanism of action of CFH in HCC 
and other cancers remains to be understood. 
  Meiotic recombination 11 homolog A (MRE11A) is a nuclear 
protein involved in homologous recombination, maintenance 
of telomere length, and DNA double-strand break repair. MRE11A 
is an important component of the MRE11 complex, which is in-
volved in checkpoint activation and DNA repair to prevent chro-
mosomal instability. Null mutation of MRE11A is known to be Yang JD, et al.  •  Genes Associated with Recurrence of HCC
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lethal in higher eukaryotes and a truncating mutation of MRE11A 
is associated with an ataxia-telangiectasia-like disorder syndrome 
(23). In breast cancer, 7% of tumors showed aberrantly reduced 
protein expression for MRE11A and it has been suggested as a 
candidate familial cancer predisposing gene (24). Our result sug-
gests that this gene acts as an oncogene which is contradictory 
to its presumed role in breast cancer. 
  Autophagy-related protein LC3 A (MAP1LC3A) is a protein 
located in the autophagosomal/autolysosomal membranes and 
antibodies directed against MAP1LC3A have been used to de-
tect autophagic activity. There are three different patterns of au-
tophagic expression. Of these, high expression of stone like struc-
ture MAP1LC3A was associated with poor prognosis in breast 
and endometrial cancers (25, 26). Our study could not provide 
specific information on the subcellular expression pattern of 
MAP1LC3A. Roles for MRE11A and MAP1LC3A in hepatocar-
cinogenesis have not been reported before and their potential 
regulation by methylation and functional roles in liver carcino-
genesis remain to be more fully characterized. 
  Several genes that were selected in our study have not previous-
ly been reported as cancer-associated genes. Myosin 1E (MYO1E) 
is a class I myosin that is comprised of a single motor domain, a 
neck domain and a cargo-biding tail domain. MYO1E appears 
to be involved in receptor mediated endocytosis through inter-
actions with synaptojanin-1 and dynamin (27). Myosin VIIA and 
Rab interacting protein (MYRIP) is a protein linking Rab27a and 
Myosin VIIa and involved in melanosome transport in the reti-
nal pigment epithelium (28). MYO1E links protein kinase A to 
the exocytosis machinery for the coordination of cellular events 
and also plays an important role in hemostasis by regulating the 
release of vWF from endothelial cells (29). NADH dehydroge-
nase 1 alpha subcomplex assembly factor 1 (NDUFAF1) is a mi-
tochondrial chaperone protein involved in the assembly of the 
mitochondrial NADH (30). Functional roles for MYRIP, MYO1E, 
and NDUFAF1 have not been reported in cancer and potential 
mechanisms for their roles in HCC remain to be determined. 
  Our study has several weaknesses. Although we selected genes 
that are associated with recurrence by both mRNA expression 
and CpG site methylation in order to focus on genes showing 
methylation-mediated regulation of gene expression (concom-
itant hypomethylation and increased expression, or concomi-
tant hypermethylation and decreased expression), the results 
do not provide direct evidence that promoter methylation of the 
selected genes regulates gene expression in HCC. The associa-
tion between gene expression and recurrence was investigated 
in the validation data set, but due to a lack of corresponding in-
formation on genome-wide methylation in the validation data 
set, the association between CpG site methylation and recur-
rence could not be validated. Nevertheless the analysis identi-
fied a number of genes that have been previously reported as 
regulated by methylation in HCC, confirming its utility for iden-
tifying methylation regulated genes, and also identified poten-
tial novel oncogenes or tumor suppressor genes in HCC for fur-
ther evaluation by functional studies. Some of the genes select-
ed by regression analysis show significant differences in recur-
rence free survival (MRE11A & CFH), however others (PSRC1, 
MYO1E, MYRIP) show a trend towards a difference in survival 
without significance when expression/methylation patterns 
were dichotomized (Fig. 3). This may be due to loss of statistical 
power from the conversion of continuous predictors to binary 
predictors. Lastly few genes that were known to be oncogenes 
or tumor suppressor genes in the previous literature were not 
completely validated in our analysis. This might have been attrib-
uted to chance from multiple comparisons. However, it is still 
meaningful to discuss them as 1) they were shown to be associ-
ated with HCC recurrence both by gene expression and methyl-
ation that have minimized the false positive association: 2) these 
are biologically plausible. 
  In conclusion, our study suggests potential novel oncogenes 
(PSRC1, MRE11A, MYO1E), tumor suppressor genes (CFH, 
MYRIP), and their enriched pathways (cytoskeleton remodel-
ing_TGF, Wnt, and cytoskeletal remodeling) implicated in he-
patocarcinogenesis that may be regulated by CpG site methyla-
tion, and affect prognosis after resection for HCC. Several of the 
identified genes and pathways have been reported in other can-
cers but are novel in HCC and other genes and pathways asso-
ciated with HCC were confirmed in our study. The regulation of 
individual genes by promoter methylation, their enriched path-
ways, and prognostic roles in HCC will need to be further vali-
dated using functional studies.
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